General Information of Drug (ID: DM0GUSX)

Drug Name
Ranitidine Drug Info
Synonyms
Achedos; Acidex; Alquen; Atural; Axoban; Biotidin; Coralen; Curan; Duractin; Ezopta; Fendibina; Gastrial; Gastridina; Gastrolav; Gastrosedol; Istomar; Kuracid; Logast; Mauran; Melfax; Microtid; Noctone; Ptinolin; Quantor; Quicran; RND; Radinat; Randin; Raniben; Raniberl; Ranibloc; Ranidine; Ranifur; Ranin; Raniogas; Raniplex; Ranisen; Raniter; Ranitidin; Ranitidina; Ranitidinum; Ranitiget; Ranitin; Rantacid; Rantidine; Ratic; Raticina; Sampep; Sostril; Taural; Terposen; Ulceranin; Ulcex; Ultidine; Urantac; Verlost; Vesyca; Vizerul; Weichilin; Weidos; Xanidine; ZANTAC; Zantab; Zantadin; Zantic; Ranitidine HCL; Rantidine HCL; Nu-Ranit; Rani-Q; Rani-nerton; Ranitidina [INN-Spanish]; Ranitidine (TN); Ranitidinum [INN-Latin]; Ul-Pep; Zantac (TN); Ranitidine (USAN/INN); Ranitidine [USAN:BAN:INN]; N-(2-((5-((Dimethylamino)methyl)furfuryl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; N (2-(((5-((Dimethylamino)methyl)-2-furanyl)methyl)thio)ethyl)-N'-methyl-2-nitro-1,1-ethenediamine; (E)-1-N'-[2-[[5-(dimethylaminomethyl)furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]-2-furyl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine; (E)-N-{2-[({5-[(dimethylamino)methyl]furan-2-yl}methyl)sulfanyl]ethyl}-N'-methyl-2-nitroethene-1,1-diamine
Indication
Disease Entry ICD 11 Status REF
Gastric ulcer DA60 Approved [1]
Gastrinoma 2C10.1 Approved [1]
Peptic ulcer DA61 Approved [2]
Therapeutic Class
Antiulcer Agents
Cross-matching ID
PubChem CID
3001055
ChEBI ID
CHEBI:8776
CAS Number
CAS 82530-72-1
TTD Drug ID
DM0GUSX
VARIDT Drug ID
DR00163
INTEDE Drug ID
DR1393
ACDINA Drug ID
D00583

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
DOT
Drug Status:
Approved Drug(s)
Discontinued Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Histamine H2 receptor (H2R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [16]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [16]
Nizatidine DMGFV3Z Acid-reflux disorder DA22 Approved [17]
Betazole DMUFGAY Gastric secretory disorder DD90 Approved [18]
Ebrotidine DMV5KR3 Duodenal ulcer DA63 Withdrawn from market [19]
Pibutidine DMXSTRM Ulcerative colitis DD71 Discontinued in Phase 3 [20]
Osutidine DMN7TL8 Duodenal ulcer DA63 Discontinued in Phase 3 [21]
KU-1257 DMZMFX6 Duodenal ulcer DA63 Discontinued in Phase 3 [22]
Lavoltidine DMTY5VE Gastroesophageal reflux disease DA22.Z Discontinued in Phase 2 [23]
IGN-2098 DMU4N1O Duodenal ulcer DA63 Discontinued in Phase 2 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [25]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [26]
Methotrexate DM2TEOL Anterior urethra cancer Approved [6]
Folic Acid DMEMBJC Colorectal carcinoma Approved [27]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [6]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [6]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [28]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [6]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [29]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [30]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [31]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [32]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [33]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [34]
Erythromycin DM4K7GQ Acne vulgaris ED80 Approved [35]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [36]
Aciclovir DMYLOVR Genital herpes 1A94 Approved [37]
Entecavir DM7VTQO Hepatitis B virus infection 1E51.0 Approved [38]
Theophylline DMRJFN9 Bronchitis CA20 Approved [35]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [39]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [40]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [41]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [42]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [43]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [44]
Propranolol DM79NTF Angina pectoris BA40 Approved [45]
Ergotidine DM78IME Osteoarthritis FA00-FA05 Approved [46]
Metformin DM89QE1 Colorectal carcinoma Approved [47]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [45]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [48]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [40]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [49]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [50]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [51]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [25]
Verapamil DMA7PEW Angina pectoris BA40 Approved [52]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [53]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [54]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [55]
Propranolol DM79NTF Angina pectoris BA40 Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [56]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [33]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [34]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [57]
Pravastatin DM6A0X7 Adult acute monocytic leukemia Approved [58]
L-Tryptophan DMIBH7M Depression 6A70-6A7Z Approved [59]
Mercaptopurine DMTM2IK Acute lymphoblastic leukaemia 2A85 Approved [60]
PITAVASTATIN CALCIUM DM1UJO0 Dyslipidemia 5C80-5C81 Approved [61]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [62]
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [63]
Valsartan DMREUQ6 Chronic heart failure BD1Z Approved [107]
Methotrexate DM2TEOL Anterior urethra cancer Approved [108]
Cidofovir DMA13GD Cytomegalovirus infection 1D82 Approved [109]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [57]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [4]
Cefdinir DMJ7A0H Bacterial infection 1A00-1C4Z Approved [110]
Cefaclor DMJXDGC Bacterial infection 1A00-1C4Z Approved [110]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [111]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [39]
Quercetin DM3NC4M Obesity 5B81 Approved [112]
⏷ Show the Full List of 20 Drug(s)
Drug(s) Metabolized By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [64]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [65]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [66]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [67]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [68]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [69]
Etoposide DMNH3PG Acute myelogenous leukaemia 2A41 Approved [70]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [71]
Verapamil DMA7PEW Angina pectoris BA40 Approved [72]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [73]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [74]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [75]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [76]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [77]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [78]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [79]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [80]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [81]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [82]
Propranolol DM79NTF Angina pectoris BA40 Approved [83]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Mephenytoin 4-hydroxylase (CYP2C19)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Acute otitis media AB00 Approved [84]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [85]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [86]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [87]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [88]
Verapamil DMA7PEW Angina pectoris BA40 Approved [89]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [90]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [91]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [92]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [93]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Dimethylaniline oxidase 5 (FMO5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nomifensine DMCP2TS Breast cancer 2C60-2C65 Withdrawn from market [9]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [94]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [95]
Trospium chloride DM32XZT Discovery agent N.A. Approved [96]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [97]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [98]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [99]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [100]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [101]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [98]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [102]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aspirin DM672AH Acute coronary syndrome BA41 Approved [98]
Methotrexate DM2TEOL Anterior urethra cancer Approved [103]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [104]
Paclitaxel DMLB81S Breast carcinoma Approved [32]
Allopurinol DMLPAOB Gout FA25 Approved [32]
Bumetanide DMRV7H0 Congestive heart failure BD10 Approved [32]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [32]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [32]
Tetracycline DMZA017 Acne vulgaris ED80 Approved [32]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [98]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [95]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [105]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [105]
Lamivudine DMI347A Chronic HBV infection 1E51.0Z Approved [97]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [4]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [98]
Trospium chloride DM32XZT Discovery agent N.A. Approved [96]
Phenoxybenzamine DM8KSQH Malignant essential hypertension BA00 Approved [94]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [106]
Indomethacin DMSC4A7 Bursitis Approved [98]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Renin (REN)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acebutolol DM0TI4U Hypertension BA00-BA04 Approved [113]
Nitrendipine DM21C09 Hypertension BA00-BA04 Approved [114]
Reboxetine DM26PRD Depression 6A70-6A7Z Approved [115]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [116]
Ramipril DM2R68E Acute heart failure BD10-BD13 Approved [117]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [118]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [119]
Epinephrine DM3KJBC Acute asthma CA23 Approved [120]
Chlorthalidone DM4DMBT Edema MG29 Approved [121]
Trandolapril DM4L6EU Chronic heart failure BD1Z Approved [122]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Prolactin (PRL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Verapamil DMA7PEW Angina pectoris BA40 Approved [123]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [124]
Citalopram DM2G9AE Acute coronary syndrome BA41 Approved [125]
Methotrexate DM2TEOL Anterior urethra cancer Approved [126]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [127]
Naloxone DM3FXMA Narcotic depression 6A7Z Approved [128]
Aripiprazole DM3NUMH Bipolar I disorder Approved [129]
Fluoxetine DM3PD2C Bipolar depression Approved [130]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [131]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [132]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Calcitonin (CALCA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fructose DM43AN2 Vomiting MD90 Approved [133]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [134]
Panobinostat DM58WKG Chronic graft versus host disease Approved [135]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [136]
Folic Acid DMEMBJC Colorectal carcinoma Approved [137]
Nizatidine DMGFV3Z Acid-reflux disorder DA22 Approved [10]
Capsaicin DMGMF6V Back pain ME84.Z Approved [138]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [139]
Azacitidine DMTA5OE Acute myelogenous leukaemia 2A41 Approved [140]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [141]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Gastrin (GAST)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [142]
Terbutaline DMD4381 Asthma CA23 Approved [143]
Cimetidine DMH61ZB Acid-reflux disorder DA22 Approved [13]
Sodium lauryl sulfate DMLJ634 Constipation DD91.1 Approved [144]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [139]
Famotidine DMRL3AB Gastric ulcer DA60 Approved [13]
Lansoprazole DMXYLQ3 Gastric ulcer DA60 Approved [145]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [146]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [11]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [147]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Protachykinin-1 (TAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [148]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [149]
Fluphenazine DMIT8LX Psychotic disorder 6A20-6A25 Approved [150]
Panobinostat DM58WKG Chronic graft versus host disease Approved [135]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [102]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [151]
Nizatidine DMGFV3Z Acid-reflux disorder DA22 Approved [10]
Capsaicin DMGMF6V Back pain ME84.Z Approved [152]
Sodium lauryl sulfate DMLJ634 Constipation DD91.1 Approved [144]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [153]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [102]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [142]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [154]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [155]
Perazine DM2AOTZ Psychotic disorder 6A20-6A25 Approved [156]
Almogran DM7I64Z Migraine 8A80 Approved [157]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [158]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [159]
Docetaxel DMDI269 Advanced cancer 2A00-2F9Z Approved [160]
Clozapine DMFC71L Schizophrenia 6A20 Approved [161]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [108]
Salicyclic acid DM2F8XZ Acne vulgaris ED80 Approved [98]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [98]
Quercetin DM3NC4M Obesity 5B81 Approved [112]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [98]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [98]
Succinic acid DMDWICP Malnutrition 5B50-5B71 Approved [162]
Mefenamic acid DMK7HFI Dysmenorrhea GA34.3 Approved [98]
Probenecid DMMFWOJ Acute gonococcal cervicitis Approved [163]
Diclofenac DMPIHLS Chronic renal failure GB61.Z Approved [98]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [164]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [165]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histamine H2 receptor (H2R) TTQHJ1K HRH2_HUMAN Antagonist [3]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [4]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [5]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [4]
Organic anion transporter 3 (SLC22A8) DTVP67E S22A8_HUMAN Substrate [4]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [8]
Dimethylaniline oxidase 5 (FMO5) DEBMX7C FMO5_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Calcitonin (CALCA) OTZ11LHB CALC_HUMAN Gene/Protein Processing [10]
Cobalamin binding intrinsic factor (CBLIF) OTNE20WU IF_HUMAN Drug Response [11]
Flavin-containing monooxygenase 3 (FMO3) OT1G2EV3 FMO3_HUMAN Regulation of Drug Effects [12]
Gastrin (GAST) OTD0IP9N GAST_HUMAN Gene/Protein Processing [13]
Organic anion transporter 3 (SLC22A8) OT8BY933 S22A8_HUMAN Regulation of Drug Effects [4]
Prolactin (PRL) OTWFQGX7 PRL_HUMAN Protein Interaction/Cellular Processes [14]
Protachykinin-1 (TAC1) OTM842YW TKN1_HUMAN Gene/Protein Processing [10]
Renin (REN) OT52GZR2 RENI_HUMAN Gene/Protein Processing [15]
Solute carrier family 22 member 1 (SLC22A1) OT7817I4 S22A1_HUMAN Regulation of Drug Effects [5]
Solute carrier family 22 member 2 (SLC22A2) OTGFK1AL S22A2_HUMAN Regulation of Drug Effects [4]

References

1 Ranitidine FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1234).
3 Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
4 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
5 Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J Pharmacol Exp Ther. 2005 Dec;315(3):1288-97.
6 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
7 Oxidation of ranitidine by isozymes of flavin-containing monooxygenase and cytochrome P450. Jpn J Pharmacol. 2000 Oct;84(2):213-20.
8 Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther. 1999 Apr;65(4):369-76.
9 Drug metabolism by flavin-containing monooxygenases of human and mouse. Expert Opin Drug Metab Toxicol. 2017 Feb;13(2):167-181.
10 Effects of histamine H(2)-receptor antagonists on human plasma levels of calcitonin gene-related peptide, substance P and vasoactive intestinal peptide. J Pharm Pharmacol. 2002 Nov;54(11):1559-63. doi: 10.1211/002235702117.
11 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
12 Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Dispos. 2004 Nov;32(11):1247-53. doi: 10.1124/dmd.104.000026. Epub 2004 Jul 30.
13 Effects of three H2-receptor antagonists (cimetidine, famotidine, ranitidine) on serum gastrin level. Int J Clin Pharmacol Res. 2002;22(2):29-35.
14 [Impotence and gynecomastia secondary to hyperprolactinemia induced by ranitidine]. Therapie. 1994 Jul-Aug;49(4):361-2.
15 Effects of histamine H2-receptor blockade on the cardiovascular reflex response to lower-body negative pressure in man. Acta Physiol Scand. 1990 May;139(1):161-72. doi: 10.1111/j.1748-1716.1990.tb08909.x.
16 Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
17 Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
18 Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
19 Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
20 Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
21 Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
22 Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
23 New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
24 Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.
25 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
26 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
27 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
28 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
29 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
30 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
31 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
32 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
33 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
34 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
35 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
36 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
37 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
38 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
39 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
40 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
41 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
42 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
43 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
44 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
45 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
46 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
47 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
48 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
49 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
50 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
51 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
52 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
53 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
54 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
55 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
56 Methotrexate-loxoprofen interaction: involvement of human organic anion transporters hOAT1 and hOAT3. Drug Metab Pharmacokinet. 2004 Oct;19(5):369-74.
57 Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol Pharmacol. 2001 May;59(5):1277-86.
58 Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug-drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab Dispos. 2011 Jun;39(6):1031-8.
59 Murine renal organic anion transporters mOAT1 and mOAT3 facilitate the transport of neuroactive tryptophan metabolites. Am J Physiol Cell Physiol. 2005 Nov;289(5):C1075-84.
60 Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem. 2004 Aug;90(4):931-41.
61 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
62 The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther. 2007 Sep;322(3):1221-7.
63 Aspirin and probenecid inhibit organic anion transporter 3-mediated renal uptake of cilostazol and probenecid induces metabolism of cilostazol in the rat. Drug Metab Dispos. 2014 Jun;42(6):996-1007.
64 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
65 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
66 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
67 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
68 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
69 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
70 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
71 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
72 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
73 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
74 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
75 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
76 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
77 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
78 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
79 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
80 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
81 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
82 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
83 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
84 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
85 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
86 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
87 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
88 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
89 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
90 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
91 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
92 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
93 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
94 Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36.
95 Involvement of aryl hydrocarbon receptor in the cytotoxicity of corannulene and its derivatives. Toxicol Lett. 2020 Mar 15;321:114-121. doi: 10.1016/j.toxlet.2019.12.012. Epub 2019 Dec 9.
96 Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics. Mol Pharm. 2015 Jan 5;12(1):171-8.
97 Transport of lamivudine [(-)-beta-L-2',3'-dideoxy-3'-thiacytidine] and high-affinity interaction of nucleoside reverse transcriptase inhibitors with human organic cation transporters 1, 2, and 3. J Pharmacol Exp Ther. 2009 Apr;329(1):252-61. doi: 10.1124/jpet.108.146225. Epub 2009 Jan 13.
98 Interactions of human organic anion transporters and human organic cation transporters with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 2002 Nov;303(2):534-9.
99 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
100 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
101 The pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivator. Br J Pharmacol. 2016 May;173(10):1703-15. doi: 10.1111/bph.13472. Epub 2016 Apr 8.
102 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
103 Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium. Arthritis Rheumatol. 2014 Jan;66(1):15-23.
104 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
105 Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem Toxicol. 2012 Jul;50(7):2289-93. doi: 10.1016/j.fct.2012.03.077. Epub 2012 Apr 16.
106 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
107 Uric acid accumulation in the kidney triggers mast cell degranulation and aggravates renal oxidative stress. Toxicology. 2023 Jan 1;483:153387. doi: 10.1016/j.tox.2022.153387. Epub 2022 Dec 1.
108 P-gp, MRP2 and OAT1/OAT3 mediate the drug-drug interaction between resveratrol and methotrexate. Toxicol Appl Pharmacol. 2016 Sep 1;306:27-35. doi: 10.1016/j.taap.2016.06.030. Epub 2016 Jul 1.
109 Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir. Toxicol In Vitro. 2015 Feb;29(1):251-8. doi: 10.1016/j.tiv.2014.10.019.
110 Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol. 2005 Oct 1;70(7):1104-13.
111 Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur J Pharmacol. 2004 Oct 25;503(1-3):25-30.
112 Potent Inhibitors of Organic Anion Transporters 1 and 3 From Natural Compounds and Their Protective Effect on Aristolochic Acid Nephropathy. Toxicol Sci. 2020 Jun 1;175(2):279-291. doi: 10.1093/toxsci/kfaa033.
113 Addition of acebutolol to diuretics in hypertension. Clin Pharmacol Ther. 1981 Dec;30(6):739-44. doi: 10.1038/clpt.1981.232.
114 Relative potency of a beta-blocking and a calcium entry blocking agent as antihypertensive drugs in black patients. Eur J Clin Pharmacol. 1986;29(5):523-7. doi: 10.1007/BF00635887.
115 Influences of norepinephrine transporter function on the distribution of sympathetic activity in humans. Hypertension. 2006 Jul;48(1):120-6. doi: 10.1161/01.HYP.0000225424.13138.5d. Epub 2006 May 22.
116 Effects of sulindac and naproxen on prostaglandin excretion in patients with impaired renal function and rheumatoid arthritis. Am J Med. 1990 Sep;89(3):313-21. doi: 10.1016/0002-9343(90)90344-d.
117 Effects of an angiotensin converting enzyme inhibitor, ramipril, on intracranial circulation in healthy volunteers. off. Br J Clin Pharmacol. 1992 Sep;34(3):224-30. doi: 10.1111/j.1365-2125.1992.tb04128.x.
118 Inhibition of cGMP-specific phosphodiesterase type 5 reduces sodium excretion and arterial blood pressure in patients with NaCl retention and ascites. Am J Physiol Renal Physiol. 2005 May;288(5):F1044-52. doi: 10.1152/ajprenal.00142.2004. Epub 2004 Dec 21.
119 beta-Endorphin and essential hypertension: importance of the clonidine-naloxone interaction. Acta Physiol Hung. 1985;65(2):217-26.
120 Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med. 1983 Dec 8;309(23):1414-9. doi: 10.1056/NEJM198312083092303.
121 Detection of low-renin hypertension; evaluation of out-patient renin-stimulating methods. Clin Sci Mol Med. 1975 Feb;48(2):91-6. doi: 10.1042/cs0480091.
122 Dosage dependent hormonal counter regulation to combination therapy in patients with left ventricular dysfunction. J Clin Pharm Ther. 2006 Apr;31(2):139-47. doi: 10.1111/j.1365-2710.2006.00606.x.
123 Verapamil-induced hyperprolactinemia complicated by a pituitary incidentaloma. Ann Pharmacother. 1995 Oct;29(10):999-1001. doi: 10.1177/106002809502901009.
124 Differential effects of estrogen receptor antagonists on pituitary lactotroph proliferation and prolactin release. Mol Cell Endocrinol. 2005 Jul 15;239(1-2):27-36. doi: 10.1016/j.mce.2005.04.008.
125 Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. Brain. 2009 Feb;132(Pt 2):392-401. doi: 10.1093/brain/awn326. Epub 2009 Jan 19.
126 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
127 The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report. Gen Hosp Psychiatry. 1985 Oct;7(4):364-6. doi: 10.1016/0163-8343(85)90053-2.
128 Influence of naloxone on muscle sympathetic nerve activity, systemic and calf haemodynamics and ambulatory blood pressure after exercise in mild essential hypertension. J Hypertens. 1995 Apr;13(4):447-61.
129 The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials. J Affect Disord. 2009 May;115(1-2):18-26. doi: 10.1016/j.jad.2008.12.017. Epub 2009 Feb 23.
130 Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. J Clin Psychiatry. 2006 Jun;67(6):952-7. doi: 10.4088/jcp.v67n0612.
131 Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol. 1985 Oct;12(5):990-1.
132 Hyperprolactinaemia induced by proton pump inhibitor. J Pak Med Assoc. 2010 Aug;60(8):689-90.
133 Non-nutritional sweeteners effects on endothelial vascular function. Toxicol In Vitro. 2020 Feb;62:104694. doi: 10.1016/j.tiv.2019.104694. Epub 2019 Oct 23.
134 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
135 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
136 The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol. 2009 Feb 15;235(1):124-34.
137 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
138 Transient receptor potential vanilloid 1-mediated expression and secretion of endothelial cell-derived calcitonin gene-related peptide. Regul Pept. 2008 Oct 9;150(1-3):66-72. doi: 10.1016/j.regpep.2008.05.007. Epub 2008 Jun 3.
139 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
140 Intriguing response to azacitidine in a patient with juvenile myelomonocytic leukemia and monosomy 7. Blood. 2009 Mar 19;113(12):2867-8. doi: 10.1182/blood-2008-12-195693.
141 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
142 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
143 L-type calcium channels regulate gastrin release from human antral G cells. Am J Physiol. 1997 Aug;273(2 Pt 1):G281-8. doi: 10.1152/ajpgi.1997.273.2.G281.
144 CXCL14 downregulation in human keratinocytes is a potential biomarker for a novel in vitro skin sensitization test. Toxicol Appl Pharmacol. 2020 Jan 1;386:114828. doi: 10.1016/j.taap.2019.114828. Epub 2019 Nov 14.
145 Influence of lansoprazole on intragastric 24-hour pH, meal-stimulated gastric acid secretion, and concentrations of gastrointestinal hormones and enzymes in serum and gastric juice in healthy volunteers. Digestion. 1995;56(2):137-44. doi: 10.1159/000201233.
146 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
147 Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013 Feb;27(1):37-48. doi: 10.1007/s10557-012-6427-8.
148 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
149 Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. Rheumatology (Oxford). 2006 Jun;45(6):765-70. doi: 10.1093/rheumatology/kei253. Epub 2006 Jan 31.
150 Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci. 2005 Mar;21(6):1712-8. doi: 10.1111/j.1460-9568.2005.04002.x.
151 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
152 Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendage structures. Exp Dermatol. 2004 Mar;13(3):129-39. doi: 10.1111/j.0906-6705.2004.0178.x.
153 Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clin Pharmacol Ther. 2016 Apr;99(4):432-41.
154 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
155 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
156 Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl). 2000 Sep;151(4):312-20.
157 Identification of the human liver enzymes involved in the metabolism of the antimigraine agent almotriptan. Drug Metab Dispos. 2003 Apr;31(4):404-11.
158 Identification and functional analysis of common human flavin-containing monooxygenase 3 genetic variants. J Pharmacol Exp Ther. 2007 Jan;320(1):266-73. doi: 10.1124/jpet.106.112268. Epub 2006 Oct 18.
159 Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res. 2004 Dec 15;10(24):8357-62. doi: 10.1158/1078-0432.CCR-04-1073.
160 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
161 Interindividual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to cytochrome P450-specific inhibition in human hepatic microsomes. Drug Metab Dispos. 2008 Dec;36(12):2547-55. doi: 10.1124/dmd.108.023671. Epub 2008 Sep 22.
162 Lack of efflux of diglycolic acid from proximal tubule cells leads to its accumulation and to toxicity of diethylene glycol. Toxicol Lett. 2023 Apr 15;379:48-55. doi: 10.1016/j.toxlet.2023.03.007. Epub 2023 Mar 22.
163 Inhibition of organic anion transporter (OAT) activity by cigarette smoke condensate. Toxicol In Vitro. 2017 Oct;44:27-35.
164 Molecular characterization of a toxicological tipping point during human stem cell differentiation. Reprod Toxicol. 2020 Jan;91:1-13. doi: 10.1016/j.reprotox.2019.10.001. Epub 2019 Oct 7.
165 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.